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Ketamine, a Brighter Future for Those
in Darkness
Matthew Gayhart, Faculty Mentor: Bonnie Boaz

Abstract
Millions of people around the world suffer from Major Depressive
Disorder, and many of these people are given drugs to help treat this
potentially devastating disease. For many, the first treatment is
successful, and if not, certainly the second treatment gives them the
relief they so desperately need. Others, however, are not so lucky,
people with treatment resistant depression undergo numerous
treatments, some of which are more aggressive than others, but still
nothing helps alleviate their depression. Recently an older anesthetic, the
drug Ketamine, has been making some news as a new depression
treatment. This paper will compare Ketamine to the traditional
approaches for treating depression, as well as discuss the next steps in
making this drug more widely available. By reviewing scholarship on the
subject of antidepressants, as well as available research on Ketamine,
and by interviewing a patient who recently underwent a Ketamine
treatment, this research highlights the positive results of Ketamine while
acknowledging the setbacks that still currently exist, and advocates for
the use of Ketamine as a treatment for depression.

Ketamine Facts
Ketamine was developed in 1962 as an anesthetic, it was used in
Vietnam on the battlefield, for it was an anesthetic that did not affect
the respiratory system, so only one doctor was needed. Since then,
Ketamine has made its way onto the Drug Enforcement
Administration’s radar as a schedule III non narcotic substance
(Sewell, 2007).
The Ketamine treatment involves 6 infusions of a low dosage of
Ketamine over the course of two weeks.
The effects of traditional antidepressants take several weeks to
become appreciable. Ketamine’s effects are seen usually within 24
hours of the first treatment.

Steven P. Levine, M.D.
One of the few doctors in the country to
offer Ketamine infusions. He is based in
Princeton, NJ and is willing to help anyone
who is suffering.

Results/Discussion
Many clinical trials have been performed using Ketamine,
however, none of them have included a placebo group. The trials
primarily focus on the relation between the Ketamine treatments
and the changes in the patient’s depression and or suicidality levels.
Rot, et.al (2010) did one such study, in which they treated ten
patients with six infusions of Ketamine over the course of two
weeks. They recorded the patients’ depression levels prior to and
after each infusion. They found that the average reduction in
depression levels was 85% (Rot). They found reductions of that
level after the two week treatment was completed, most typical
antidepressants take that long or longer to show any effect at all,
and even then it is not usually as pronounced as with Ketamine. Dr.
Levine (2013), is one of the handful of doctors that currently offers
the Ketamine treatment, and he has personally completed the
treatment on over 100 patients. He reports that he has not had a
single case with any negative side effects, nor any lasting negative
reactions. His results also fall in line with previous tests, with a high
percentage of patients having a significant decrease in depression
levels (Levine). Ketamine has produced positive results for
individuals who may never have experienced a successful
depression treatment.

“Mean (modified) Montgomery-Åsberg Depression Rating Scale (MADRS) and Quick Inventory of Depressive Symptoms, SelfReport Version (QIDS-SR16) scores before (t0) and 4 hours after (t+4h) six intravenous ketamine infusions in nine patients who
responded to a single infusion and subsequently received five additional infusions.” (Rot, 2010)

Conclusion
Ketamine has the potential to save thousands of lives every single year, but
there are still a few problems standing in the way of it truly being a viable
option to treat depression. First, there are not enough doctors or hospitals
offering the treatment, as it is highly specialized and is not an approved
treatment. Second, the cost of Ketamine can be high; this comes in part from
the lack of insurance support. Insurance would be more likely to cover the cost
of the treatment if it were an FDA approved treatment for depression.
However, regardless of these shortfalls hindering the widespread use of
Ketamine, the drug is out there and, while there may be a waiting list and an
extremely large price tag, relief can be reached by many. With public support,
Ketamine can be seen as the life saving drug that it has the potential to be, but
the first step towards change is knowledge. More trials and more research must
be conducted on the safety and efficacy of Ketamine, but that should not stop
it from saving people, people who have no where else to turn.
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Further Information
To keep up to date with current Ketamine news visit:
http://ketamineadvocacynetwork.org/
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